August 21, 2018 – 5:42 AM
The National Institute of Health (INS) reported that during the first respiratory peak of the year, 141 deaths occurred throughout the country due to influenza AH1N1, mainly in children younger than 2 years, adults over 60 years and people with chronic diseases such as diabetes and obesity , among others.
According to the institution, two people died in January, followed by February with 6 deaths, March (4), April (11), May (43), June (59) and July with 16 deaths, in the departments of Chocó, Guainía. , Vaupés, Santander, Norte de Santander, Sucre and Cartagena, where business continues to increase.
"This figure confirms the historical behavior of this type of flu, which on average represents a significant increase in the number of cases every two years, not only in Colombia, but also in the countries of the North and South America," said institute.
Also read: There are already 38 cases of H1N1 flu in Cali, do you know how to prevent this?
He also noted that at the end of the first breath of the year there is no pandemic behavior of influenza AH1N1, which together with other types of flu, such as subtype AH3N2 and influenza type B, are viruses circulating in the environment within the group of acute respiratory tract infections.
With regard to acute respiratory infections (ARI) in the country, the INS reported that it had decreased by 42% compared to the weeks with the highest notification in 2018, ranging from 180,000 weekly cases to 127,000. However, he did not ask the health authorities to reduce their surveillance and to maintain preventive measures in the community and in health centers.
– Wash your hands regularly
– Avoid the greeting of hand and / or pillow.
– Do not rub your eyes or touch your face with unwashed hands.
Use mask if symptoms of flu occur.
– Adding timely health services.
In addition, vaccination against the Expanded Program of Immunization (PAI) against influenza should be considered, offering sufficient protection against the three most common types of this virus, two of subtype A (AH1N1 and AH3N2) and one of type B.
Vaccination is recommended in the following groups: children 6 to 23 months old, adults over 60 years, pregnant women, people of any age with: chronic lung diseases including asthma, people with morbid obesity, people with primary or secondary immunosuppression, people with diabetes, people with congenital, rheumatic or ischemic heart disease.